Mechanism of skin allograft enhancement across an H‐2 class I mutant difference. Evidence for involvement of veto cells
W. Martin Kast(University of Southern California), Leo P. de Waal, Cornelis J.M. Melief(ISA Pharmaceuticals (Netherlands)), E. van Twuyver(Dutch Blood Transfusion Society), Marieke Verveld(The Netherlands Cancer Institute), Rob J.D. Mooijaart(Dutch Blood Transfusion Society), Alfons G. A. Kamphuis(The Netherlands Cancer Institute)
Cited by 23
Related Papers
Therapeutic cancer vaccines
|Journal of Clinical Investigation|2015|1.1k
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells
|Nature Medicine|2002|549